Fate Therapeutics is a clinical-stage biopharmaceutical company with a clear mission: to provide innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for patients with cancer and autoimmune disorders. By focusing on the principle that better cell therapies start with better cells, Fate Therapeutics utilizes their proprietary iPSC product platform to create clonal master iPSC lines with optimal biological properties. These clonal master iPSC lines serve as a reliable and renewable cell source to manufacture off-the-shelf cell therapy products that can effectively treat a wide range of patients.

Fate Therapeutics' primary emphasis lies in the development of natural killer (NK) cell and T-cell product candidates, targeting the cells of the immune system. With a commitment to advancing a revolutionary approach to cell therapy, Fate Therapeutics aims to provide better cells for better therapies, improving the lives of those affected by cancer and autoimmune disorders